Opus Genetics gets FDA clearance to test OPGx-RDH12 gene therapy
IRD•The FDA cleared Opus Genetics’ investigational new drug application for OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis. A Phase 1/2 trial is planned to begin this quarter.
1. FDA clears application
The FDA cleared Opus Genetics’ investigational new drug application for OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis, an inherited retinal disease that causes childhood vision loss. The company plans to begin a Phase 1/2 trial this quarter.
